Detlev Biniszkiewicz

Independent Director

Dr. Detlev Biniszkiewicz (PhD) is Independent Director of the Board of Directors. He is currently CEO of portfolio company NextPoint Therapeutics and Managing Director at MPM BioImpact. Dr. Biniszkiewicz is a serial entrepreneur and an experienced biopharma executive who brings deep knowledge of oncology, business development, and biotech leadership to his role.

He has also significant prior board experiences which include iTEOs, Tilos, and Maverick Therapeutics. Prior to joining MPM and BioImpact Capital, he was the President and CEO of Surface Oncology (NASDAQ: SURF). He was also Vice President of Strategy in AstraZeneca’s Oncology Unit and was part of the leadership that developed Lynparza® and Tagrisso®. He has also held multiple roles at Novartis including Global Head of Portfolio.

Dr. Biniszkiewicz began his career at the Boston Consulting Group and performed his academic research at the Whitehead Institute at the Massachusetts Institute of Technology.